Nat Med:IL-6在治疗II型糖尿病中可能扮演关键角色

2011-11-24 MedSci原创 MedSci原创

 MedSci专家点评:  炎性分子,如IL-1,IL-6,TNFα等均被认为是“坏”分子,在器官的急性炎症和慢性炎症中均扮演关键角色。甚至,在胰岛素抵抗,冠心病形成中,都作为“坏”分子出现。因为脂肪细胞分泌这些分子,诱发胰岛素抵抗,最终形成糖尿病。 然而,我们反过来想想,为什么脂肪细胞要无缘无故分泌这些炎性分子?实际上,机体内广泛存在正负反馈机制。当脂肪细胞分泌这

 MedSci专家点评:  炎性分子,如IL-1,IL-6,TNFα等均被认为是“坏”分子,在器官的急性炎症和慢性炎症中均扮演关键角色。甚至,在胰岛素抵抗,冠心病形成中,都作为“坏”分子出现。因为脂肪细胞分泌这些分子,诱发胰岛素抵抗,最终形成糖尿病。 然而,我们反过来想想,为什么脂肪细胞要无缘无故分泌这些炎性分子?实际上,机体内广泛存在正负反馈机制。当脂肪细胞分泌这些炎性因子时,是希望通过某种机制,促进过多的脂肪分解。而肌肉中同样如此,通过分泌这些因子,促进在运动时,对糖份摄入的增加需求。而增加这种需求,需要通过GLP-1等促进糖利用的因子。 实际上,IL-6有此功能,而IL-1也应该有类似的功能。肌肉有这样的反应,同样心脏也会如此,因为在运动时心脏供能需要大量增加,仅仅通过血供增加进行供能,有时仍然难以满足需求,因此,还需要通过其它机制增加心肌细胞对能量的摄入。这种机制又是什么?诸如此类,都值得大家在临床与科研中探索。MedSci也将与大家一同探索这些未知领域...... 在11月《自然—医学》期刊上,研究人员称,他们鉴别出一种新的内分泌激素通道,显示一种促炎症细

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1879098, encodeId=fa0618e909821, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 18 12:32:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273743, encodeId=36ca12e3743c4, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429649, encodeId=e09614296496b, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605627, encodeId=8ee4160562e0d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]
    2012-09-18 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1879098, encodeId=fa0618e909821, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 18 12:32:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273743, encodeId=36ca12e3743c4, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429649, encodeId=e09614296496b, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605627, encodeId=8ee4160562e0d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]
    2011-11-26 kzlchina
  3. [GetPortalCommentsPageByObjectIdResponse(id=1879098, encodeId=fa0618e909821, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 18 12:32:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273743, encodeId=36ca12e3743c4, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429649, encodeId=e09614296496b, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605627, encodeId=8ee4160562e0d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1879098, encodeId=fa0618e909821, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 18 12:32:00 CST 2012, time=2012-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273743, encodeId=36ca12e3743c4, content=<a href='/topic/show?id=fae896e7ea' target=_blank style='color:#2F92EE;'>#IL-6#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9677, encryptionId=fae896e7ea, topicName=IL-6)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1429649, encodeId=e09614296496b, content=<a href='/topic/show?id=9a8d9592b0' target=_blank style='color:#2F92EE;'>#II型糖尿病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9592, encryptionId=9a8d9592b0, topicName=II型糖尿病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d7914226234, createdName=lsj629, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605627, encodeId=8ee4160562e0d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Nov 26 10:32:00 CST 2011, time=2011-11-26, status=1, ipAttribution=)]